During the past decade, York PCI Group Inc conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "York PCI Group Inc" are "Acute Myocardial Infarction" (1 trials), "Coronary Artery Disease" (1 trials), "Hemorrhage" (1 trials), "Invasive Procedure" (1 trials) and "Urgent Surgery" (1 trials). Many other conditions were trialed in "York PCI Group Inc" in a lesser frequency.

Most popular intervention types in "York PCI Group Inc" are "Combination Product" (1 trials), "Device" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)" (1 trials), "Bentracimab (PB2452) Infusion" (1 trials), "Microport Firehawk stent" (1 trials), "Placebo" (1 trials) and "Selatogrel" (1 trials). Other intervention names were less common.

The vast majority of trials in "York PCI Group Inc" are 3 trials for "All" genders.

Currently, there are NaN active trials in "York PCI Group Inc". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were undefined completed trials in York PCI Group Inc, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in York PCI Group Inc, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".